Displaying 271 - 280 of 516
Endocrine University® Year 1 – February 20-22, 2025, is a 3-day virtual program designed to provide a forum for fellows-in-training to enhance their endocrine curriculum in disease and practice management skills. Year 1 focuses on skills and technology training in diabetes, thyroid, and new technology.
Jacksonville, FL (July 18, 2023)—The American Association of Clinical Endocrinology (AACE) is pleased to announce that it has retained Suzanne Berry, MBA, CAE, to serve as the Interim Chief Executive Officer.
"We will be launching some bold new initiatives and anticipate your engagement and support in the coming months. Suzanne assumed her role on July 3, 2023. The board and the staff look forward to working with her closely in achieving our mission:
Elevating the Practice of Clinical Endocrinology to Improve Global Health," said S. Sethu K. Reddy, MD, MBA, FRCPC…
more
Access our obesity courses featuring the latest advancements and information on improving obesity diagnosis and treatment.
Co-sponsored by Endocrine Society, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.
This 2017 guideline‒led by the Endocrine Society and co-sponsored with AACE, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health‒is an update of the 2009 Endocrine Society guideline on endocrine treatment…
more
These six case discussions present clinical vignettes to illustrate some of the key recommendations for diagnosis, treatment, and long-term management of transgender children and adults in the Endocrine Society's 2017 guideline, co-sponsored by AACE, on endocrine treatment of persons with gender dysphoria/gender incongruence.
Read Consensus Statement moreThis statement addresses the prevalence of macroprolactin in patients with hyperprolactinemia and macroprolactin’s relevance regarding clinical decision-making about laboratory testing, imaging, and pharmacologic or surgical treatment.
Read Consensus Statement moreThis statement addresses neuroendocrine evaluation, testing, and management of patients with traumatic brain injury‒induced hypopituitarism or those at risk for hypopituitarism.
Read Consensus Statement moreThis statement employs case studies to discuss evaluation, early diagnosis, surgical treatment, and ongoing management of endocrinopathies in patients with multiple endocrine neoplasia, type 2.
Read Consensus Statement moreCarcinoid tumors, which most commonly originate from the small intestine, are either referred to as small intestinal neuroendocrine tumors or midgut carcinoids. This statement addresses diagnostics and therapeutics for patients with midgut carcinoids and provides an overview of multidisciplinary care to improve quality of life, treatment outcomes, and survival.
Read Consensus Statement moreThis statement addresses incidental detection of pancreatic neuroendocrine tumors, imaging-based characterization for differential diagnoses, prognosis, and appropriate management.
Read Consensus Statement more
